Core Insights - Liquidia Corporation will provide a business update during a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 p.m. ET in Boston [1] - Investors and interested parties can access a webcast of the presentation on Liquidia's website, with an archived version available for at least 30 days post-event [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's current focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]